CTIS2023-507981-17-00进行中（未招募）1 期
Colchicine for ischemia with no obstructive coronary artery disease and microvascular dysfunction - 2023-507981-17-00
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Have CMD, defined as myocardial blodflow reserve (MBFR) < 2.5 or hyperemic myocardial blood flow (hMBF) < 2.3ml/g/min, •No obstructive CAD as determined by the clinical assessment of [15O]H2O-PET
排除标准
- •Females of childbearing potential. The female patient must either be postmenopausal for at least 1 year or surgically sterile., •Patient with a history of an allergic reaction or sensitivity to adenosine or mannitol., •Patient with Atrioventricular block grade II or III, or sick sinus syndrome, not protected by a pacemaker., •Patient currently taking colchicine for other indications (mainly chronic indications represented by Familial Mediterranean Fever or gout). There is no wash-out period required for patients who have been treated with colchicine and stopped treatment prior to enrolment., •Patients with severe hypovolemia or hypotension (defined as systolic blood pressure < 90mmHg), •Patients with unstable angina pectoris, •Patient with increased intracranial pressure., •Patient with a history of an allergic reaction or significant sensitivity to colchicine., •Patient in treatment with Potent CYP3A4-/P-gp-inhibitors: oAmiodaron oAmprenavir* oAtazanavir* oClarithromycin* oDiltiazem oErythromycin oTelithromycin oAzitromycin oFluvoxamin oFosamprenavir* oIndinavir* oItraconazol* oKetoconazol* oLopinavir oSaquinavir oNelfinavir oFosamprenavir oIndinavir oRitonavir* oVerapamil oVoriconazol* oPyridamole oRoxithromycin oCiclosporine oOr has a massive Grapefruit consumption, •Patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study., •Patient with heart failure, defined as left ventricular ejection fraction of less than 40%[44], •Male patients who are planning to impregnate their partner within the individual participation period in the trial and 6 months after last dose., •Patient with uncontrolled hypertension (defined as blood pressure above target 140/90 for all) ), •Patient with inflammatory bowel disease (Crohn’s disease or ulcerative colitis) or patient with chronic diarrhea., •Patient with any of the following as measured within the past 30 days, and determined to be non-transient through repeat testing: Anemia, thrombocytopenia, leucopenia, liver disease, or kidney disease defined as any of the following measurements within the last 3 months: ohemoglobin < 7mmol/L, owhite blood cell count < 3.0 X 109/L, oplatelet count <110 X 109/L, oALT > 3 times the upper limit of normal, ototal bilirubin > 2 times upper limit of normal oSerum Creatinine >150mmol/l or eGFR<50mL/min, •Patients in treatment with anticoagulants.NOACs: Eliquis, Lixiana, Pradaxa, Xarelto, or Warfarin, patient with severe valve disease, •Patient with a history of cirrhosis, chronic active hepatitis, or severe hepatic disease., •Patient with a history of clinically significant drug or alcohol abuse in the last year., •Patient is currently using or plans to begin chronic systemic steroid therapy (oral or intravenous) during the study (topical or inhaled steroids are allowed)., •Patient with liver disease, •Patient with kidney disease or kidney impairment, defined as Serum Creatinine >150mmol/l or eGFR<50mL/min, •Male patients, having intercourse with fertile women, not willing to use contraception., •Patient with lactose intolerance
研究者
相似试验
招募中
1 期
COLchicine in BElgium in patients with coronary artery disease after Percutaneous Coronary InterventioCoronary artery diseaseMedDRA version: 20.0Level: PTClassification code: 10011078Term: Coronary artery disease Class: 100000004849CTIS2023-505028-74-00niversitair Ziekenhuis Gent2,770
已完成
2 期
COCOMO-ACS Study: The Colchicine for coronary plaque modification in Acute Coronary Syndrome StudyCardiovascular - Coronary heart diseaseCoronary Artery DiseaseAcute Coronary SyndromeNon-ST elevation myocardial infarctionACTRN12618000809235South Australian Health and Medical Research Insititute64
进行中（未招募）
1 期
Colchicine for the Treatment of Hyperinflammation associated with Pneumonia due to COVID-19Hyperinflammation associated with Pneumonia due to COVID19EUCTR2020-001841-38-ESSociedad Española de Cardiología240
进行中（未招募）
1 期
COLCOT Studypatients with atherosclerotic coronary artery disease (CAD)MedDRA version: 20.0Level: HLGTClassification code 10011082Term: Coronary artery disordersSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: PTClassification code 10028596Term: Myocardial infarctionSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: SOCClassification code 10007541Term: Cardiac disordersSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: HLTClassification code 10011085Term: Ischaemic coronary artery disordersSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: LLTClassification code 10028595Term: Myocardial infarctSystem Organ Class: 10007541 - Cardiac disordersEUCTR2014-005172-28-ITMONTREAL HEART INSTITUTE4,500
进行中（未招募）
1 期
Colchicine Cardiovascular Outcomes Trialpatients with atherosclerotic coronary artery disease (CAD)EUCTR2014-005172-28-PTMontreal Heart Institute4,500